Updated NCCN Guidelines Will Expand Rare Disease Diagnosis

Shared on30 Apr 25
Fair value Decreased 6.83%

Shared on23 Apr 25
Fair value Increased 0.38%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Increased 6.93%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Increased 2.87%

Shared on26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25
Fair value Increased 5.54%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on11 Mar 25
Fair value Decreased 3.87%

AnalystConsensusTarget has decreased revenue growth from 13.9% to 9.9%.